Abstract
Background/Aim: Reports indicate that coronaviridae may inhibit insulin secretion. In this report we aimed to describe the course of glycemia in critically ill patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Patients and Methods: We studied 36 SARS-CoV-2 patients (with no history of diabetes) in one intensive care unit (ICU). All the patients were admitted for hypoxemic respiratory failure; all but four required mechanical ventilation. The mean (±SD) age of the patients was 64.7 (9.7) years; 27 were men; the mean (±SD) duration of ICU stay was 12.9 (8.3 days). Results: Twenty of 36 patients presented with hyperglycemia; brief intravenous infusions of short-acting insulin were administered in six patients. As of May 29 2020, 11 patients had died (seven with hyperglycemia). In 17 patients the Hyperglycemia Index [HGI; defined as the area under the curve of (hyper)glycemia level*time (h) divided by the total time in the ICU] was <16.21 mg/dl (0.90 mmol/l), whereas in three patients the HGI was ≥16.21 mg/dl (0.90 mol/l) and <32.25 mg/dl (1.79 mmol/l). Conclusion: In our series of ICU patients with SARS-CoV-2 infection, and no history of diabetes, a substantial number of patients had hyperglycemia, to a higher degree than would be expected by the stress of critical illness, lending credence to reports that speculated a tentative association between SARS-CoV-2 and hyperglycemia. This finding is important, since hyperglycemia can lead to further infectious complications.
Coronaviridae [such as severe acute respiratory syndrome coronavirus-1 (SARS-CoV-1) or Middle East Respiratory Syndrome coronavirus (MERS-CoV)] have been shown – in experimental conditions and at the cellular level – to inhibit insulin secretion (1-3). Early reports of patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection indicated that 45-52% presented with hyperglycemia, with no more than 10% having a medical history of diabetes (4, 5). Thus, an association of SARS-CoV-2 with hyperglycemia seems plausible (1), however, other reports describing the glycemic profile of patients admitted to the intensive care units (ICU) with SARS-CoV-2 are lacking. Better characterization of the glycemic profile of patients with SARS-CoV-2 infection in critically ill patients could be useful in guiding clinical decisions, since hyperglycemia may lead to further infectious complications (6). The aim of our single-center study was to describe the course of glycemia in critically ill patients with SARS-CoV-2 in one of the seven ICUs dedicated to the management of these patients in the metropolitan Athens capital area.
Patients and Methods
We included patients with laboratory-confirmed SARS-CoV-2 infection who were admitted to the Evangelismos hospital ICU in the Athens capital region between March 20 and May 3, 2020 (the largest of the seven public health system ICUs dedicated to providing care for SARS-CoV-2 patients in the region). All the patients were admitted for hypoxemic respiratory failure. The patient data were censored upon the study's cutoff, on May 29, 2020. Cases were considered as having SARS-CoV-2 infection based on positive results of reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assays of nasopharyngeal swab specimens; only cases with laboratory confirmation were included. Forty adults (with an age of 18 years or older) were identified. Exclusion criteria included pregnancy and prior medical history/diagnosis of any form of diabetes (to search for previous existence of diabetes we assessed physician documentation, Hellenic National Health service electronic records and queried the patients' next of kin). The data were summarized with descriptive statistics; quantitative results are reported as means and standard deviations, while qualitative results are given as counts. The study was approved by the Scientific Council/Ethics Board of the Evangelismos Hospital (No 170/April 24, 2020); written informed consent for inclusion of anonymized data for publication was obtained from the patients or their next of kin. We excluded four patients with a medical history of diabetes and studied 36 patients (27 men; mean age±SD=64.7±9.7 years) for up to 10 days. Their mean±SD admission APACHE and SOFA scores were 16±4 and 8±2, respectively. Eighteen patients were obese (BMI>30 kg/m2), 13 were smokers, 16 were treated for hypertension, six were treated for hyperlipidemia, one was on levothyroxine supplementation for hypothyroidism; ten patients had more than one coexisting condition. Admission data are presented in Table I. All the patients upon admission had imaging studies (CT scan) showing bilateral pulmonary opacities (ground glass) and hypoxemia (mean±SD PaO2/FIO2 was 160±67). Thirty-two patients received mechanical ventilation. Twenty-seven patients received antiviral therapy (lopinavir) and 24 received hydroxychloroquine and azithromycin; 21 received inotropes.
Graph of glucose over time during ICU hospitalization of a patient with Hyperglycemia Index (HGI) of 25.632 mg/dl or 1.424 mmol/l (A) and of a patient with HGI: 3.376 mg/dl or 0.187 mmol/l (B); the HGI is calculated from the shaded area divided by total time in the ICU as per (7).
Blood glucose was measured upon admission and thereafter for three times per day (at approximately 07:00, 14:00 and 20:00). Overall, more than 1.000 blood glucose measurements were analyzed. During ICU hospitalization target glycemia was set between 110-179 mg/dl (6.10-9.93 mmol/l). Hyperglycemia >180 mg/dl (10.00 mmol/l) was evaluated over time by calculating the Hyperglycemia Index [HGI; defined as the area under the curve of (hyper)glycemia level*time (hours) divided by the total time in the ICU] (Figure 1) (7). Statistical analysis for the frequency of hyperglycemia was done with the one-sample Chi square test, assuming an expected frequency of hyperglycemia of 25% (n=9), 33% (n=12) or 50% (n=18).
Data of patients (n=36) upon ICU admission.
Results
Twenty out of 36 patients had hyperglycemia; in 17 patients the HGI was <16.21 mg/dl (0.90 mmol/l), whereas in three patients the HGI was ≥16.21 mg/dl (0.90 mol/l) and <32.25 mg/dl (1.79 mmol/l) (Figure 1). In 16 patients blood glucose did not exceed 179 mg/dl (9.93 mmol/l). The observed frequency of hyperglycemia was statistically significant for expected frequencies of hyperglycemia of 25% or 33% but not for 50% (Chi-squared=17.926, 8.000 and 0.444 and p=0.0002, 0.0004 and 0.505, respectively). Hyperglycemia was treated with brief intravenous infusion of short-acting insulin in six patients.
As of May 29 2020, 11 of the patients had died (seven with hyperglycemia; mean±SD duration of ICU stay was 13.2±12.2 days), seven were receiving mechanical ventilation and were still in the ICU and 18 had been discharged from the ICU after 8.3±6.6 days.
Discussion
Twenty-five percent of critically ill patients with no history of diabetes have stress hyperglycemia (the underlying endogenous mechanisms may include the release of counter-regulatory hormones, alteration of insulin receptor signaling due to inflammation and inhibition of pancreatic beta-cell function) (8). In our series of ICU patients with SARS-CoV-2, and no history of diabetes, a substantial number of patients had hyperglycemia, corroborating the findings from the early phases of the SARS-CoV-2 pandemic in China, where approximately half of the hospitalized patients were noted to have hyperglycemia (4, 5). Hyperglycemia was also noted in some non-diabetic patients in a series of SARS-CoV-2 patients from the United States; in this series admission hyperglycemia was associated with chest imaging findings (9).
Coronaviridae such as SARS-CoV-1 or MERS-CoV, have been shown to cause failure of the islets of Langerhans and activation of dipeptidyl peptidase 4 (DPP4), respectively, thus inhibiting insulin secretion; SARS-CoV-2-may also provoke hyperglycemia (the mechanisms are not elucidated yet) (1-3). Thus, our findings may lend credence to reports that showed hyperglycemia in patients with SARS-CoV-2 infection (mostly with diabetes but also without diabetes) and speculated a tentative association between SARS-CoV-2 and hyperglycemia (1, 4, 5, 10).
This is possibly the largest – to date – study on glycemia in critically ill non-diabetic patients with SARS-CoV-2 infection. There are caveats in our study: sample size could be considered to be low and there was no control group for proper comparisons (however, for expected frequencies of 25% or 33% with α=0.05, the post hoc power of the study was calculated to be 97% or 79%, respectively). Continuous glucose monitoring (CGM) would also be helpful, providing more complete and dynamic data of glycemia over time. Additionally, another factor modulating glycemia might have been the administration of hydroxychloroquine. The latter has been shown to increase the sensitivity to insulin (11, 12). Thus, a possible effect of SARS-CoV-2 on glycemia might have been suppressed, as therapeutic levels of hydroxychlo-roquine increased. The study of new-onset hyperglycemia in non-diabetic patients with SARS-CoV-2 infection is an active field of research and worldwide relevant data are currently being gathered, especially with the ongoing CoviDIAB Project (13).
Conclusion
In our series of ICU patients with SARS-CoV-2, and no history of diabetes, a substantial number of patients had hyperglycemia, to a higher degree than would be expected by the stress of critical illness. This finding lends credence to reports that have speculated a tentative association between SARS-CoV-2 infection and hyperglycemia, by - yet – undefined mechanisms. This new-onset hyperglycemia may be clinically important, since it can lead to further infectious complications.
Acknowledgements
Research for this report did not receive specific funding, but was performed as part of the employment of the authors at Evangelismos Hospital and Elena Venizelou Hospital, Athens, Greece.
Footnotes
Authors' Contributions
All Authors collected data and prepared the article; statistical analysis was done by II and ID.
This article is freely accessible online.
Data Availability
The anonymized data for this report are available upon request to the Authors.
Conflicts of Interest
The Authors have no conflicts of interest to report.
- Received June 9, 2020.
- Revision received June 29, 2020.
- Accepted June 30, 2020.
- Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved
